Zhaoke Ophthalmology Limited (06622.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 2.49

From 52W high−37.81%

Volume224000.00

Market capHKD 1.37B

P/E (TTM)—

P/S (TTM)33.7x

Div yield—

Key dataSep 18, 2026

Open

HKD 2.49

From 52W high

−37.81%

Volume

224000.00

Market cap

HKD 1.37B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.0x

P/E (TTM)

—

RSI (14)

47.7

MomentumView details →

1D Return

+0.60%

YTD Return

−15.54%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−2.0x

EV/Sales

12.2x

P/S (TTM)

33.7x

P/B (TTM)

0.8x

ProfitabilityView details →

Gross Margin

−101.92%

Net Margin

−614.52%

EBITDA Margin

−623.02%

ROE (TTM)

−15.39%

ROA (TTM)

−12.29%

Asset Turnover

0.02x

GrowthView details →

Revenue YoY

−1.72%

EPS YoY

+26.92%

FCF YoY

+57.91%

Revenue CAGR 3Y

+28.89%

EPS CAGR 3Y

+13.95%

EBITDA YoY

+26.96%

MomentumView details →

1D Return

+0.60%

YTD Return

−15.54%

1Y Return

−34.55%

RSI (14)

47.7

vs 50D SMA

−1.52%

vs 200D SMA

−14.14%

Capital & dividendView details →

Debt/Equity

0.19x

Current Ratio

3.41x

Quick Ratio

3.37x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−HKD 0.25

EPS Surprise

11.84%

Beats (12Q)

1/12

Next Q EPS Est

−HKD 0.53

Avg Surprise (4Q)

11.84%

Rev Surprise

398.28%

Financials snapshotView financials →

Revenue (TTM)

70.11M

Net Income (TTM)

−491.86M

Op. CF (TTM)

−329.57M

Next earningsMar 29, 2027 →

Latest newsMore news →

Zhaoke Ophthalmology announced that its YUVEZZI eye drop reached the primary endpoint in a Phase II clinical study in China for presbyopia patients, and plans to advance to Phase III clinical trials.14d ago

Zhaoke Ophthalmology signed an exclusive distribution and promotion agreement with Pengpai Biomedical for its epinastine hydrochloride eye drops (brand: Mingyanshu) covering all sales channels in mainland China, with an initial five-year term and possible extension to ten years.39d ago

Similar companies

LB Pharmaceuticals Inc Common StockLBRX First Tracks Biotherapeutics IncTRAX Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.02566.HK Damora Therapeutics, Inc.DMRA ASCENTAGE PHARMA GROUP INTERNATIONALAAPG Alpha Tau Medical Ltd.DRTS Find similar companies →

Latest newsMore news →

Zhaoke Ophthalmology announced that its YUVEZZI eye drop reached the primary endpoint in a Phase II clinical study in China for presbyopia patients, and plans to advance to Phase III clinical trials.14d ago Zhaoke Ophthalmology signed an exclusive distribution and promotion agreement with Pengpai Biomedical for its epinastine hydrochloride eye drops (brand: Mingyanshu) covering all sales channels in mainland China, with an initial five-year term and possible extension to ten years.39d ago